{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:59:58Z","timestamp":1780520398158,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":915,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1124\/dmd.121.000818","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T11:25:24Z","timestamp":1651577124000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework"],"prefix":"10.1016","volume":"50","author":[{"given":"Mian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kilford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic Y.","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000818_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1019703607647","article-title":"A compartmental model of hepatic disposition kinetics: 1. Model development and application to linear kinetics","volume":"29","author":"Anissimov","year":"2002","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.121.000818_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/psp4.12275","article-title":"Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug-drug interactions: CYP3A\/2C9 induction and OATP inhibition effects","volume":"7","author":"Asaumi","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","article-title":"Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects","volume":"62","author":"Backman","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00228-007-0389-y","article-title":"Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine","volume":"64","author":"Backman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1208\/s12248-009-9103-6","article-title":"Prediction of hepatic clearance in human from in vitro data for successful drug development","volume":"11","author":"Chiba","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000818_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/dmd.118.081315","article-title":"Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro\u2013in vivo scaling of hepatic uptake clearance","volume":"46","author":"De Bruyn","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000818_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clpt.2005.06.009","article-title":"Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2","volume":"78","author":"Granfors","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000818_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000818_bib10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","article-title":"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","volume":"76","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000818_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000818_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000818_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2007.01660.x","article-title":"A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients","volume":"62","author":"Henney","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1124\/dmd.121.000818_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000818_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.100375","article-title":"Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: impact of drug-drug interactions and cigarette consumption","volume":"37","author":"Jogiraju","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000818_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00228-007-0456-4","article-title":"Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo","volume":"64","author":"Karjalainen","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.clpt.6100149","article-title":"Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4","volume":"81","author":"Lilja","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000818_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.118.082966","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds","volume":"46","author":"Lombardo","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000818_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cpt.539","article-title":"Physiologically based pharmacokinetic modeling in regulatory decision-making at the European Medicines Agency","volume":"102","author":"Luzon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000818_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdd.2072","article-title":"Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon","volume":"38","author":"Pade","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000818_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.07.025","article-title":"Hepatic clearance concepts and misconceptions: why the well-stirred model is still used even though it is not physiologic reality?","volume":"169","author":"Pang","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00228-011-1189-y","article-title":"Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2","volume":"68","author":"Plowchalk","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF01062125","article-title":"Availability predictions by hepatic elimination models for Michaelis-Menten kinetics","volume":"17","author":"Roberts","year":"1989","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.121.000818_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.2042-7158.1986.tb04540.x","article-title":"Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model","volume":"38","author":"Roberts","year":"1986","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000818_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/psp4.52","article-title":"Physiologically based pharmacokinetics is impacting drug development and regulatory decision making","volume":"4","author":"Rowland","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/psp4.12203","article-title":"Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective","volume":"6","author":"Sato","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1208\/s12249-009-9241-2","article-title":"Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets","volume":"10","author":"Shanker","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1124\/dmd.121.000818_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-9556(24)15277-4","article-title":"A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state","volume":"27","author":"Shellenberger","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000818_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijpharm.2008.10.001","article-title":"Estimation of effective intestinal membrane permeability considering bile micelle solubilisation","volume":"368","author":"Sugano","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.121.000818_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1472-8206.1987.tb00581.x","article-title":"Pharmacokinetics of orally administered tizanidine in healthy volunteers","volume":"1","author":"Tse","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.121.000818_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","article-title":"Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders","volume":"53","author":"Wagstaff","year":"1997","journal-title":"Drugs"},{"key":"10.1124\/dmd.121.000818_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000818_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ecp.13.4","article-title":"Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach","volume":"6","author":"Yeo","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/dmd.121.000818_bib35","first-page":"S160","article-title":"Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions to the US FDA\u2019s office of clinical pharmacology","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624008316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:01:35Z","timestamp":1740765695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624008316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0090955624008316"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000818","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}